Skip to main content
. Author manuscript; available in PMC: 2017 Sep 15.
Published in final edited form as: Cancer Res. 2016 Sep 15;76(18):5209–5218. doi: 10.1158/0008-5472.CAN-15-2106

Figure 3.

Figure 3

Tumor progression influences dynamics of leukocyte populations at the PCL scaffold. Percentage of (A) CD11b+F4/80+ (B) CD11c+F4/80− (C) Gr-1hiCD11b+Ly6C− (D) Ly6C+F4/80− innate immune cell populations and percentage of (E) CD4+ (F) CD8+ (G) CD19+ and (H) CD49b+ adaptive immune cell populations in the total population of live CD45+ leukocytes at day 0, 3, 7, 14, and 21 post tumor inoculation (N ≥ 8 for each time point examined, *p < 0.05 compared to day 0 and #p < 0.05 compared to day 3 as determined by Tukey-HSD test post ANOVA). Error bars denote s.e.m.